丙型肝炎病毒感染作为初次腰椎融合术后并发症和费用增加的预测因素
这项回顾性队列研究纳入2005至2014年因退变性腰椎病理接受初次腰椎融合术的联邦医疗保险患者28841例,比较HCV血清阳性(无活动性肝病)与匹配对照组的90天并发症、再入院和费用。HCV组输血、肺炎、呼吸衰竭、尿路感染、伤口/植入物感染、脑血管事件及任何并发症的比值比均显著升高,手术当日和90天费用也更高,但住院时长和90天再入院率无显著差异。
要点
- HCV血清阳性患者90天内任何并发症的OR为2.93(P<0.0001)。
- HCV组输血OR 3.06、肺炎OR 2.49、呼吸衰竭OR 2.49,均P<0.0001。
- HCV组手术当日费用$28,713.26 vs 对照组$25,448.26,P<0.0001。
核心结论
- 在接受初次腰椎融合术的患者中,无肝病的HCV血清阳性与更高的费用和并发症率相关,包括更高的输血需求和肺炎相关并发症。
- 该数据为HCV患者的择期脊柱手术提供了新认识,可能影响外科医生考虑对该人群行腰椎融合时的风险与获益权衡。
研究设计与样本
- 回顾性队列研究,查询2005至2014年国家数据库,纳入因退变性腰椎病理接受初次腰椎融合术的联邦医疗保险患者。
- 最终分析队列28841例,HCV患者按人口学、治疗方式和合并症与非HCV对照组匹配,并采用多变量逻辑回归分析。
- 排除活动性肝病患者以更好地分离HCV作为合并症的影响。
主要发现
- 与无HCV感染者相比,HCV感染者输血OR为3.06、肺炎OR为2.49、呼吸衰竭OR为2.49、尿路感染OR为1.89、伤口/植入物相关感染OR为1.74、脑血管事件OR为1.70、90天内任何术后并发症OR为2.93,所有P<0.0001。
- HCV阳性患者手术当日费用为$28,713.26 vs 对照组$25,448.26,90天费用为$33,447.39 vs 对照组$29,016.77,均P<0.0001。
- HCV感染患者与无HCV感染者在住院时长(10天 vs 8天,P=0.332)和90天再入院率(0.37% vs 0.22%;OR 1.70,95%CI 1.00-2.90,P=0.050)方面无显著差异。
关键数值与推荐
- HCV组90天内任何术后并发症OR 2.93(P<0.0001)。
- HCV组输血OR 3.06、肺炎OR 2.49、呼吸衰竭OR 2.49(均P<0.0001)。
- HCV组尿路感染OR 1.89、伤口/植入物相关感染OR 1.74、脑血管事件OR 1.70(均P<0.0001)。
- HCV组手术当日费用$28,713.26 vs 对照组$25,448.26(P<0.0001);90天费用$33,447.39 vs 对照组$29,016.77(P<0.0001)。
- 90天再入院率HCV组0.37% vs 对照组0.22%(OR 1.70,95%CI 1.00-2.90,P=0.050),住院时长10天 vs 8天(P=0.332)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY DESIGN: Retrospective cohort study. OBJECTIVE: The aim of this study was to identify whether hepatitis C virus (HCV) diagnosis influences in-hospital lengths of stay (LOS), postoperative complications, readmission rates, or costs following primary posterior lumbar fusions in an elective setting. SUMMARY OF BACKGROUND DATA: Although joint arthroplasty literature has shown increased complication rates and costs for patients seropositive with HCV without liver disease compared to those without HCV, this comorbidity has not been explored in the spine literature. To our knowledge, this is the first publication in the lumbar spine literature to solely focus on HCV as the disease burden. METHODS: A national database was queried for patients who underwent primary lumbar spine fusion for degenerative lumbar pathology with Medicare insurance from 2005 to 2014. The 90-day postoperative complication rates, readmission rates, and treatment costs were queried. To limit confounding, HCV patients were matched with a control cohort of non-HCV patients using patient demographics, treatment modality, and comorbid conditions, and then analyzed by multivariate logistic regression. Patients with active liver disease were excluded to better isolate HCV as the comorbidity. RESULTS: A cohort of 28,841 patients were included in the final analysis. Postoperatively, compared to those without HCV infection, those with HCV had significantly higher odds of blood transfusions (odds ratio [OR]: 3.06), pneumonia (OR: 2.49), respiratory failure (OR: 2.49), urinary tract infections (OR: 1.89), wound-/implant-related infections (OR: 1.74), cerebrovascular events (OR: 1.70), or any postoperative complication within 90 days (OR: 2.93; all P < 0.0001). Furthermore, HCV positive patients had higher day of surgery costs ($28,713.26 vs. $25,448.26, P < 0.0001) and 90-day costs ($33,447.39 vs. $29,016.77, P < 0.0001). There was not a significant difference for patients with HCV infection compared to those without in regard to hospital LOS (10 days vs. 8 days, P = 0.332) and rates of a 90-day readmission (0.37% vs. 0.22%; OR: 1.70, 95% confidence interval: 1.00-2.90, P: 0.050). CONCLUSION: In patients undergoing primary lumbar fusion, a seropositivity for HCV without liver disease is associated with higher costs and complication rates, including higher rates of blood transfusion requirements and pneumonia-related complications. This data shed new light on elective spine surgery in HCV patients and may influence the risks and benefits considerations for surgeons considering lumbar fusion in this population. LEVEL OF EVIDENCE: 3.
引用
- Donnally CJ, Patel PD, Canseco JA, et al. Hepatitis C Virus Infection as a Predictor of Complications and Increased Costs Following Primary Lumbar Fusion Surgery. Spine (Phila Pa 1976). 2020. PMID: 32706565. doi:10.1097/BRS.0000000000003481
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。